当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Dr. Srimath BS, Dr. Sagar Thippanna Porammanavar, Dr. Ameeth Kulkarni
Chondrosarcomas are the second most common bone sarcomas, accounting for less than 0.5% of all cancers. The treatment plan can be improved by analyzing clinical characteristics and treatment patterns. The rarity and slowgrowing nature of this tumour often lead to prolonged symptoms and also initial misdiagnosis with avascular necrosis of the femur, benign bone lesions like chondroblastoma [1]. The initial reports of this patient suggested avascular necrosis of the femur head. His pain became severe and further investigations were done, MRI confirmed the diagnosis of Chondrosarcoma. An image-guided core needle biopsy suggested Clear Cell Chondrosarcoma (CCC). Wide local resection with negative margins forms the mainstay of treatment since intralesional procedures predispose to a high local recurrence rate. A prolonged follow-up is required since late local recurrences of tumour and distant metastases are common.